Fampridine-SR – Treatment for Multiple Sclerosis
Key Data:
Drug (Brand/Generic)
Fampridine-SR (4-aminopyridine)
Company/Licensee
Acorda Therapeutics
Therapy Class
Potassium channel blocker
Product Description
Selective neuronal potassium (K+) channel blocker
Current Indication
Treatment of MS
Market Sector
CNS
Development Status
Phase III trials involving MS patients completed; NDA under review by the US FDA
